Our principal, Ms. Pauli Wong, was invited to speak at the Hong Kong Life Sciences Society (HKLSS) Summer Internship Program 2024 on “Unlocking Patent Law: Exploring IP Career Paths” in July. This program aims to cultivate young talents to drive life sciences innovation. In addition, she participated in the discussion session titled “Evolving Landscape – Investment Outlook for the Healthcare and Life Sciences Sectors” alongside Mr. Tian Tan, the Vice President of NF Trinity.

Pauli shared her career journey becoming a patent attorney at Eagle IP, from an HKU biotech graduate and a scientist with CK Life Sciences. She provided an introduction to intellectual property, particularly patents, and life sciences challenges we are facing, and how to pursue a career path in patent law. By sharing her own experiences, Pauli offered valuable insights and guidance to the aspiring interns to appreciate the importance of IP and consider a career path in patent law.

Our Past Events

Recommended Insights

Can Post Filing Data Overcome Inventive Step in China?

19 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

China Finally Clamps Down on Facial Recognition Technology

24 August 2021
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

12 November 2018
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
Top crossarrow-right